Based in Brisbane this medical device company for vaccine delivery is using a game-changing micro-needle technology (NanopatchTM) developed at the University of Queensland.
Prof. Mark Kendall who heads the research team developing the Nanopatch received the Translational Research Excellence Commercialisation Award for the Nanopatch and Vaxxas was a finalist in
the Enterprize Business Plan competition in 2010.
Vaxxas has attracted $15 million of investment to continue development of the Nanopatch and take it to clinical trials. Investors, led by OneVentures, include Brandon Capital, the Medical Research
Commercialisation Fund (MRCF) and US-based HealthCare Ventures.